Alzheimer's Disease
Agitation from Alzheimer's disease?
Explore a Clinical Trial for Those Not Finding Relief with
Current Medications.
Alzheimer’s disease (AD) is the most common form of
dementia, accounting for 60 - 70% of cases worldwide. Over 55 million people
currently live with dementia, and this number is projected to nearly double
every 20 years - reaching 78 million by 2030 and 139 million by 2050. A
significant symptom of AD is agitation, which affects about 50% of patients and
contributes to worsened disease progression, poor quality of life, higher
mortality rates, and increased institutionalization. Agitation also places a heavy
burden on caregivers, increasing the risk of anxiety, depression, and the
decision to institutionalize their loved ones. If you or a loved one are
experiencing symptoms of agitation associated with Alzheimer’s disease you may
be eligible for a clinical trial. Learn more today.
Eligible Participants Are:
- 55 – 95 years of age
- Experiencing agitation associated with Alzheimer's disease
- 18 – 40 BMI
- Additional criteria may apply
Eligible Participants May:
- Receive compensation for study related time and travel
- See a physician or medical staff for study related care at
no cost
» Study Details | Apply for the Study
|